NURSING EXPERIENCE MONITORING AND MANAGEMENT OF PATIENTS RECEIVING TARLATAMAB, A BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, FOR SMALL CELL LUNG CANCER (SCLC)

I27

  • Gray, Sunshine MSN, RN
  • Pons, Alba Silverio RN
  • Kelley, Elaine RN, MSN, OCN
  • McDonald, Stephanie MSN, FNP-BC, AOCNP

  • 1Swedish Cancer Institute, Seattle, WA

    2Vall d'Hebron University Hospital, Barcelona, Catalonia

    3Dana Farber Cancer Institute, Boston, MA

    4Dana Farber Cancer Institute, Boston, MA

Oncology Nursing Forum 51(2):p E314, March 2024.
Copyright © 2024 Oncology Nursing Society